Quick Answer
Cullinan Therapeutics, Inc. reported Total Assets of $448.37 million for fiscal year 2025.
Cullinan Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $448.37M | -27.9% |
| 2024 | $621.82M | +28.4% |
| 2023 | $484.18M | -13.7% |
| 2022 | $561.12M | +28.3% |
| 2021 | $437.19M | +103.6% |
| 2020 | $214.71M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $484.13M | -25.9% | -7.0% |
| June 30, 2025 | $520.33M | -23.6% | -10.2% |
| March 31, 2025 | $579.68M | +29.0% | -6.8% |
| December 31, 2024 | $621.82M | +28.4% | -4.8% |
| September 30, 2024 | $653.25M | +32.0% | -4.1% |
| June 30, 2024 | $681.22M | +30.5% | +51.6% |
| March 31, 2024 | $449.43M | -12.7% | -7.2% |
| December 31, 2023 | $484.18M | -13.7% | -2.1% |
- Cullinan Therapeutics, Inc. showed a decrease of -27.9% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Cullinan Therapeutics, Inc.’s total assets has grown by 108.8% (from $214.71 million to $448.37 million).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: